Clive Dix: Industry Veteran, Vaccines Expert And Biotech Advocate
Executive Summary
With more than 30 years’ experience in pharma and biotech, Clive Dix has seen the industry evolve and take on many challenges. He spoke to Scrip about his career journey, the future of biotech and his expectations for 2022 – another year under the cloud of COVID-19.
You may also be interested in...
UK Terminates COVID-19 Vaccine Deal, But Valneva Can Bounce Back
The UK’s decision has hit Valneva’s share price hard, but its vaccine candidates in Chikungunya and Lyme’s disease should help the firm bounce back.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.